Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs). 

Biotechnology

Therapeutics

Lyell Immunopharma

Lynn Seely

Artem Yankov

Pradeep Ravindra

Chris Michon

Manjit Dokal

Stasiu Nowak

Julie Urvater

Jennifer Fleischer

Cynthia Shumate

Vonnie Vo

Erik Green

Senai Teklemichael

Marly Puckett

Eric Hoffmann

Karen Duffy-Simons

Julie Jeffery

Dana Langworthy

Alisha Lewis

Rick Watt

Danielle Kulman

Kimberly Henson

Wen Liu

Joanna Karas

Shipra G.

Joseph Maguire

Ellen Rose

Matthew Lang

Charles Newton

Tina Albertson

Gary Lee

Stephen Hill

The executive team at Lyell Immunopharma has a long history of experience in the sales and marketing of HER2+ breast cancer portfolios, global regulatory operations, project management, talent operations, and biologics manufacturing. They also have a strong educational background, with degrees from some of the top universities in the world.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Lyell Immunopharma

Board of Directors

Leadership Team